{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:32:17Z","timestamp":1649194337100},"reference-count":5,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0378-6323.191539","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T07:56:55Z","timestamp":1475827015000},"page":"684","source":"Crossref","is-referenced-by-count":0,"title":["Author reply: Biologics or biosimilars: What is the difference?"],"prefix":"10.25259","volume":"82","author":[{"given":"VinodKumar","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neetu","family":"Bhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanika","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ramam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.191539-1","first-page":"389","volume-title":"Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study","author":"Sharma","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"http:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.191539-2","first-page":"353","volume-title":"Population pharmacokinetics of Reditux\u2122, a biosimilar rituximab, in diffuse large B-cell lymphoma","author":"Gota","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.4103\/0378-6323.191539-3","first-page":"323","volume-title":"Pulse therapy as a cure for autoimmune diseases","author":"Pasricha","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"http:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.191539-4","first-page":"875","volume-title":"Dexamethasone-cyclophosphamide pulse therapy for pemphigus","author":"Pasricha","year":"1995","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.191539-5","unstructured":"Pasricha JS, editor. AIIMS experience. In: Pulse Therapy in Pemphigus and Other Diseases. 3rd ed. New Delhi: Mehta Publishers; 2006. p. 67-71."}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:45:40Z","timestamp":1611917140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/author-reply-biologics-or-biosimilars-what-is-the-difference\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"alternative-id":["191539"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.191539","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}